Sanofi S.A., FR0000120578

RBC cut target for Sanofi stock from EUR 80 to EUR 75

Published on 10/19/2026 at 10:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter results are due October 30, 2026. Sanofi stock costs EUR 71.30 on October 19, 2026, 0.88 percent below the Xetra close of EUR 71.93.

Analyst targets and growth

RBC cut its Sanofi target from EUR 80.00 to EUR 75.00 on October 16, 2026.
First-half 2026 revenue reached EUR 22.10 billion, up 15.70 percent year over year.
Sanofi stock trades at EUR 71.30 at 10:01 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.88 percent below the Xetra close of October 16, 2026.

Overhead flatlay of pharmaceutical objects on white surface including clear glass vials, a syringe, petri dish, test tubes, a pipette, and blue nitrile gloves — Sanofi FR0000120578 overhead flatlay of pharmaceutical vials, syringe, pipette, petri dish, and protective gloves, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) was trading at EUR 71.30 at Lang & Schwarz on October 19, 2026, at 10:01 a.m. CEST, down 0.88 percent versus the Xetra close of October 16, 2026 at EUR 71.93. RBC cut its Sanofi target from EUR 80.00 to EUR 75.00 on October 16, 2026, while keeping a Sector Perform rating ahead of third-quarter results.

Target cut before results

The latest analyst move puts the emphasis on execution rather than a simple growth story. RBC analyst Trung Huynh wrote that Dupixent strength may not offset pressure elsewhere and said market revenue and earnings expectations could be too high, according to RBC.

Three target views in October

The sequence shows a sharp split in expectations. On October 7, 2026, Jefferies kept a Buy rating and a EUR 100.00 target. On October 14, 2026, UBS maintained Neutral with a EUR 78.00 target. RBC then lowered its target to EUR 75.00 on October 16, 2026.

What does the EUR 75 target imply?

The RBC target is 5.18 percent above the Lang & Schwarz price of EUR 71.30, but it sits below both the UBS and Jefferies targets. The counterweight is Sanofi's operating performance: first-half 2026 revenue reached EUR 22.10 billion, up 15.70 percent from the prior-year period, according to IsraelValley.

Dates that could reset estimates

Sanofi's next reporting date is October 30, 2026, when management will review third-quarter results in a webcast, according to Sanofi. The company also lists a Jefferies Global Healthcare Conference appearance for November 17, 2026. Those dates make the next quarterly update the clearest test of whether Dupixent momentum can offset pressure in other businesses.

Stock below the analyst range

Sanofi's EUR 71.30 quote is 1.32 percent above its EUR 69.75 52-week low and 21.78 percent below its EUR 91.15 52-week high as of October 19, 2026. The market capitalization was EUR 85.4 billion on the same date. The further course of trading is shown by the continuously updated real-time quote of Sanofi stock.